



Please use a plus sign (+) inside this box →

RECEIVED

NOV 07 2002

TECH CENTER 1600/2900

gp1635

#8

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	09/840,704
		Filing Date	April 23, 2001
		First Named Inventor	DEDHAR, SHOUKAT
		Group Art Unit	1635
		Examiner Name	GIBBS, TERRA C.
Total Number of Pages in This Submission	30	Attorney Docket Number	KINE-001CON2
ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group	
<input type="checkbox"/> Fee Attached	<input checked="" type="checkbox"/> Drawing(s) - Figs. 1-6	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences	
<input checked="" type="checkbox"/> Preliminary Amendment-Certification of Sequence Listing / Response to Detailed Action: Nucleotide and/or Amino Acid Sequence Disclosure	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
<input checked="" type="checkbox"/> Copy of Detailed Action: Nucleotide and/or Amino Acid Sequence Disclosure	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information	
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter	
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):	
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1. Paper copy of Sequence Listing	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	2. Postcard	
<input type="checkbox"/> Certified Copy of Priority Documents	<input checked="" type="checkbox"/> CD, Number of CD(s) 1		
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm or Individual Name	PAMELA J. SHERWOOD, Reg. No. 36,677		
Signature			
Date	October 30, 2002		

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: October 30, 2002.			
Typed or printed name	Susan M. Alessi		
Signature		Date	October 30, 2002

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/840,704	04/23/2001	Shoukat Dedhar	KINE001CON2	5167

24353 7590 09/30/2002

BOZICEVIC, FIELD & FRANCIS LLP
200 MIDDLEFIELD RD
SUITE 200
MENLO PARK, CA 94025

COPY

EXAMINER


GIBBS, TERRA C

ART UNIT	PAPER NUMBER
----------	--------------

1635

DATE MAILED: 09/30/2002

7



Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED
NOV 07 2002
TECH CENTER 1600/2900

@10/07/02
DOCKETED
SEQ LIST 10/30/02
LD 03/30/03

RECEIVED

NOV 07 2002

Bozicevic, Field & Francis

Art Unit: 1635

**DETAILED ACTION*****Nucleotide and/or Amino Acid Sequence Disclosure***

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 Fed. Reg. 18230, May 1, 1990. It is noted that the application fails to comply with 37 CFR 1.821(a) and (d).

37 CFR 1.821(a) states, "Nucleotide and /or amino acid sequences as used in 37 CFR §1.821 through 1.825 are interpreted to mean an unbranched sequence of *four or more* amino acids or an unbranched sequence of *ten or more* nucleotides. Branched sequences are specifically excluded from this definition. Sequences with fewer than four specifically defined nucleotides or amino acids are specifically excluded from this section. "Specifically defined " means those amino acids other than "Xaa " and those nucleotide bases other than "n " defined in accordance with the World Intellectual Property Organization (WIPO) Handbook on Industrial Property Information and Documentation, Standard ST.25: Standard for the Presentation of Nucleotide and Amino Acid Sequence Listings in Patent Applications (1998), including Tables 1 through 6 in Appendix 2, herein incorporated by reference. (Hereinafter "WIPO Standard ST.25 (1998)). This incorporation by reference was approved by the Director of the Federal Register in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies of WIPO Standard ST.25 (1998) may be obtained from the World Intellectual Property Organization; 34 chemin des Colombettes;

Art Unit: 1635

1211 Geneva 20 Switzerland. Copies of ST.25 may be inspected at the Patent Search Room; Crystal Plaza 3, Lobby Level; 2021 South Clark Place; Arlington, VA 22202. Copies may also be inspected at the Office of the Federal Register, 800 North Capitol Street, NW, Suite 700, Washington, DC. Nucleotides and amino acids are further defined as follows:

- (1) Nucleotides: Nucleotides are intended to embrace only those nucleotides that can be represented using the symbols set forth in WIPO Standard ST.25 (1998), Appendix 2, Table 1. Modifications, e.g., methylated bases, may be described as set forth in WIPO Standard ST.25 (1998), Appendix 2, Table 2, but shall not be shown explicitly in the nucleotide sequence.
- (2) Amino acids: Amino acids are those L-amino acids commonly found in naturally occurring proteins and are listed in WIPO Standard ST.25 (1998), Appendix 2, Table 3. Those amino acid sequences containing D-amino acids are not intended to be embraced by this definition. Any amino acid sequence that contains post-translationally modified amino acids may be described as the amino acid sequence that is initially translated using the symbols shown in WIPO Standard ST.25 (1998), Appendix 2, Table 3 with the modified positions; e.g., hydroxylations or glycosylations, being described as set forth in WIPO Standard ST.25 (1998), Appendix 2, Table 4, but these modifications shall not be shown explicitly in the amino acid sequence. Any peptide or protein that can be expressed as a sequence using the symbols in WIPO Standard ST.25 (1998), Appendix 2, Table 3 in conjunction with a description in the Feature section to describe, for example, modified linkages, cross links and end caps, non-peptidyl bonds, etc., is embraced by this definition.

37 CFR 1.821(d) states, "Where the description or claims of a patent application discuss a sequence that is set forth in the "Sequence Listing" in accordance with paragraph (c) of this

Art Unit: 1635


section, reference must be made to the sequence by use of the sequence identifier, preceded by "SEQ ID NO:" in the text description or claims, even if the sequence is also embedded in the text of the description or claims of the patent application". For example, at page 28 of the instant specification, line 17 contains, "AAUAAA" and line 22 contains, "GXGXXG". Additionally, Figures 1A, 1B and 1C should have accompanying SEQ ID numbers. The above are examples and are not intended to indicate that the examiner has made an exhaustive review of the application. It is the duty of the applicant to fully comply with sequence rules of 37 CFR § 1.821 (a-d).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Terra C. Gibbs whose telephone number is (703) 306-3221. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John L. LeGuyader can be reached on (703) 308-0447. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 746-8693 for regular communications and (703) 872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

tcg
September 26, 2002


SEAN MCGARRY
PRIMARY EXAMINER
1635